Spago Nanomedical
A Swedish nanomedicine company in clinical development phase with a proprietary platform of polymeric materials that targets more precise diagnosis and treatment of solid tumors.
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (21 %) | - | - | 1087 % | 89 % | 47 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (18396 %) | - | (65943 %) | (5439 %) | (5881 %) | (3674 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (20119 %) | - | (67363 %) | (5535 %) | (5920 %) | (3719 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | (1291 %) | - | (2543 %) | (259 %) | (208 %) | (137 %) | - |
Source: Company filings or news article, Dealroom estimates
Related Content
Spago Nanomedical AB is a Swedish company specializing in the development of nanomedicines, currently in the clinical development phase. The company's core technology is based on a proprietary platform of polymeric materials designed to enhance the precision of imaging diagnostics and treatment for life-threatening and debilitating diseases. Spago Nanomedical primarily serves the healthcare sector, targeting medical professionals and institutions involved in the diagnosis and treatment of severe conditions. Operating in the nanomedicine market, the company aims to address unmet medical needs through advanced diagnostic and therapeutic solutions.
The business model of Spago Nanomedical involves the development and commercialization of its nanomedicine platform. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of its diagnostic and therapeutic products once they receive regulatory approval. The company is publicly traded on the Nasdaq First North Growth Market under the ticker SPAGO, providing it with access to capital markets to fund its research and development activities.
Spago Nanomedical's strategic focus includes advancing its clinical pipeline, securing regulatory approvals, and establishing commercial partnerships to bring its innovative solutions to market. The company leverages its expertise in polymeric materials and nanotechnology to create products that offer significant improvements over existing diagnostic and therapeutic options.
Keywords: nanomedicine, polymeric materials, clinical development, imaging diagnostics, therapeutic solutions, healthcare sector, regulatory approval, commercialization, Nasdaq First North, innovative solutions.